BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced that outcomes data through 42 months from the open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the 2024 AHA Scientific Sessions. The featured science oral presentation, titled 'Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes from the ATTRibute-CM Open-Label Extension (OLE) Study', will be delivered by Dr. Daniel Judge on November 18.

Additionally, BridgeBio will present three moderated digital posters on ATTR-CM, covering topics such as healthcare costs, baseline risk evolution, and acoramidis' impact on survival. These presentations will take place on November 17. The presentation and posters will be available on BridgeBio's website after the sessions.

Positive

• Acoramidis reduces all-cause mortality and cardiovascular-related hospitalization in ATTR-CM patients
• BridgeBio's research selected for featured science oral presentation at AHA Scientific Sessions
• Long-term data (42 months) from Phase 3 study to be presented
• Multiple aspects of ATTR-CM research accepted for presentation, indicating strong scientific interest

Negative

• None.

News Market Reaction – BBIO

+2.19%

1 alert

+2.19% News Effect

On the day this news was published, BBIO gained 2.19%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 – 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.

Featured Science Oral Presentation:
Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes from the ATTRibute-CM Open-Label Extension (OLE) Study
Session Title: Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations
Presenter: Daniel Judge, M.D. of Medical University of South Carolina
Date: Monday, November 18 at 9:45 am CT/10:45 am ET

Moderated Digital Posters:
Costs and Healthcare Resource Utilization in Transthyretin Amyloid Cardiomyopathy Exceeds That of Generalized Heart Failure
Session Title: Socioeconomic Insights and Innovations in Heart Failure
Presenter: Justin Grodin, M.D. of UT Southwestern Medical Center
Date: Sunday, November 17 at 10:00 am CT/11:00 am ET

Evolving Baseline Risk in Patients with Transthyretin Amyloid Cardiomyopathy: A Systematic Literature Review of Clinical Trials
Session Title: Cardiac Amyloidosis 2024: Advances in Prognostication and Management
Presenter: Ahmad Masri, M.D. of Oregon Health & Science University
Date: Sunday, November 17 at 11:10 am CT/12:10 pm ET

Acoramidis Improved Survival in Patients with Transthyretin Cardiac Amyloidosis Regardless of Prior Cardiovascular Hospitalization
Session Title: Cardiac Amyloidosis 2024: Advances in Prognostication and Management
Presenter: Kevin Alexander, M.D. of Stanford University School of Medicine
Date: Sunday, November 17 at 11:20 am CT/12:20 pm ET

The presentation and posters will be available following the sessions on the Presentations page within the Investors section of the BridgeBio website at https://investor.bridgebio.com.

About BridgeBio Pharma, Inc.
BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015, and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.

BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220

FAQ

What are the key findings from BridgeBio's ATTRibute-CM study on acoramidis for ATTR-CM (BBIO)?

The key findings show that acoramidis reduces all-cause mortality (ACM) and cardiovascular-related hospitalization (CVH) in ATTR-CM patients, based on 42-month data from the open-label extension of the Phase 3 ATTRibute-CM study.

When and where will BridgeBio (BBIO) present the ATTRibute-CM study results for acoramidis?

BridgeBio will present the results at the 2024 AHA Scientific Sessions in Chicago, Illinois, from November 16-18, 2024. The featured science oral presentation is scheduled for November 18 at 9:45 am CT.

What additional ATTR-CM research is BridgeBio (BBIO) presenting at the 2024 AHA Scientific Sessions?

BridgeBio is presenting three moderated digital posters on ATTR-CM, covering healthcare costs and resource utilization, evolving baseline risk in patients, and acoramidis' impact on survival regardless of prior cardiovascular hospitalization.

How can investors access BridgeBio's (BBIO) AHA Scientific Sessions presentations?

The presentation and posters will be available after the sessions on the Presentations page within the Investors section of BridgeBio's website at https://investor.bridgebio.com.